DGAP-News: Expedeon AG licenses Lightning-Link(R) Rapid Biotinylation technology to Cell Guidance Systems in supply agreement

PRESS RELEASE
08 January 2019

Expedeon AG licenses Lightning-Link^(R) Rapid^{Biotinylation technology to Cell Guidance Systems in supply agreement}

- License allows Cell Guidance Systems to use Lightning-Link^(R) in manufacture of
TRIFic(TM) exome detection immunoassay kits

- Expedeon becomes preferred immunoreagent supplier to Cell Guidance Systems

Heidelberg, Germany and Cambridge, UK, 08 January 2019 - Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard), today announced it has signed a supply and license agreement with Cell Guidance Systems, a developer of therapeutic products for medicine and life science research, for use of Expedeon's proprietary Lightning-Link^(R) Rapid Biotin technology in the development and production of TRIFic(TM) (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays. Cell Guidance Systems has already benefitted from the application of Expedeon's Lightning-Link^(R) technology for over two years, and under this new agreement Expedeon becomes preferred immunoreagent supplier to the company.

Cell Guidance Systems' TRIFic(TM) rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic(TM) exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples.

The Expedeon Lightning-Link^(R) Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface. The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10ug to 1g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.

Using Expedeon's Lightning-Link^(R) biotin technology will enable Cell Guidance Systems to manufacture TRIFic(TM) detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved production yields and enhanced quality of immunoassay handling.

Dr Heikki Lanckriet, CEO and CSO of Expedeon, commented: "We have been working with Cell Guidance Systems for several years and are delighted to strengthen the relationship. Our technology provides a rapid, easy to use, efficient method of labelling antibodies and we are confident it will serve Cell Guidance Systems very well in the development and production of their TRIFic detection assay kits. This latest agreement follows a number of license and supply agreements with various partners for Lightning-Link^(R), underlining the increasing demand in academia and industry for our proprietary solutions, which help drive the life sciences research sector."

Dr Laur-Alexandru Botos, Senior Research Scientist at Cell Guidance Systems said: "TRIFic(TM) kit is an exquisitely sensitive europium time resolved immunofluorescence assay for exosome markers. The Lightning-Link^(R) Rapid Biotin technology is used to generate stable biotin conjugates as components of this platform. We have found Expedeon's cutting edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFic(TM) detection assay kits enable researcher to save time and costs."

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

Cell Guidance Systems
Dr. Laur-Alexandru Botos
Phone: +44 1223 967316
Email: info@cellgs.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Phone: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###